Adherium Ltd. (OTC:ADRMF) Filings

Adherium Ltd.

Filings

FilingDateTypeFiled with
Change in substantial holdingNov 19, 2026Ownership change noticeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Additional $750,000 Loan Facility from Barvest VenturesOct 30, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 28, 2026Meeting noticeASX
Partnership with Florida Lung, Asthma & Sleep SpecialistsOct 25, 2026Operations updateASX
Appointment of Chief Financial OfficerOct 11, 2026Management or board changeASX
AUD$700,000 Short-Term Loan Facility from Barvest VenturesOct 6, 2026Other filingsASX
Appendix 4G & Corporate Governance StatementSep 30, 2026Other filingsASX
Annual Report to shareholdersSep 30, 2026Annual reportASX
Adherium Consolidates Funding into A$4.67M Term LoanSep 15, 2026FinancingASX
Preliminary Final ReportAug 31, 2026Annual reportASX
Change of Company SecretaryAug 21, 2026Management or board changeASX
Adherium enters into additional $1M short-term loan facilityAug 17, 2026FinancingASX
Ceasing to be a substantial holderJul 30, 2026Ownership change noticeASX
Adherium Announces CEO TransitionJul 28, 2026Management or board changeASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 28, 2026Quarterly reportASX
Adherium - Investor UpdateJul 26, 2026Other filingsASX
Results of Extraordinary General MeetingJun 18, 2026Meeting outcomeASX
Notice of Share ConsolidationMay 20, 2026Other filingsASX
Adherium Hailie Smartinhaler Quarter-to-Date Sales UpdateMar 10, 2026ResultsASX
Half Yearly Report and AccountsFeb 27, 2026Interim reportASX
Completion of Placement and Institutional Entitlement OfferFeb 17, 2026FinancingASX
Placement and Accelerated Non-Renounceable Entitlement OfferFeb 15, 2026FinancingASX
Equity Raising Investor PresentationFeb 15, 2026FinancingASX
Trading HaltFeb 15, 2026Trading halt or suspensionASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2026Quarterly reportASX
Adherium exceeds CY2025 device shipment milestonesDec 23, 2025ResultsASX
Adherium quarter to date sales updateDec 15, 2025ResultsASX
Adherium reaches major milestone in Allergy Partners rolloutNov 26, 2025Operations updateASX
iCARE Study Hailie Smartinhaler Improves Patient AdherenceSep 15, 2025ResultsASX
Preliminary Final ReportAug 29, 2025ResultsASX
Firm commitments received for institutional placementAug 4, 2025FinancingASX
Adherium Appoints Dawn Bitz as CEOJul 22, 2025Management or board changeASX
Successful Completion of Retail Component of ANREOJul 17, 2025FinancingASX
Replacement ProspectusJun 26, 2025Offer documentASX
Successful Completion of Institutional Component of ANREOJun 26, 2025FinancingASX
ProspectusJun 24, 2025Offer documentASX
Accel Non-Renounceable Entitlement Offer to raise up to $4mJun 24, 2025FinancingASX
$900K Capital Raise to Accelerate Smart Inhaler in USMay 19, 2025FinancingASX
Adherium Secures $2.6M to Advance Smart Inhaler in USMar 18, 2025FinancingASX
Management ChangeOct 29, 2024Other filingsASX
AstraZeneca selected Adherium Smartinhaler for its studyMay 23, 2024Operations updateASX
Non-Renounceable Rights Issue Offer CompletesMay 23, 2024FinancingASX
Placement and Entitlement Offer to raise up to $8.37 millionApr 26, 2024FinancingASX
First Patient Enrolled in Major e-health Clinical StudyMar 19, 2024Operations updateASX
Adherium receives $1.5m Australian R&D Tax RebateMar 6, 2024ResultsASX
New CEO Appointed - Dr Paul MastoridisJan 31, 2024Management or board changeASX
Resignation of CEOJan 15, 2024Management or board changeASX
Notice of Annual General Meeting/Proxy FormOct 26, 2023Meeting noticeASX
Annual Report to shareholdersAug 30, 2023Annual reportASX
Adherium SPP and Shortfall Offers ProspectusNov 17, 2022Offer documentASX
Adherium secures $13.5m in placement commitmentsSep 16, 2022FinancingASX
Adherium signs UK distribution agreement with Helicon HealthJun 14, 2022Other filingsASX
Adherium to support Avillion sponsored clinical studyJun 1, 2022Other filingsASX
Adherium awarded US-based AZ clinical study supply contractSep 24, 2021Other filingsASX
Target's StatementJun 28, 2021Offer documentASX
Letter to Shareholders re takeover offerJun 16, 2021Acquisition or disposalASX
Adherium submits next gen sensor for US FDA clearanceMay 31, 2021Other filingsASX
Replacement Bidders StatementMay 27, 2021Offer documentASX
1st Supplementary Bidder's Statement(marked up replacementMay 27, 2021Offer documentASX
Adherium announces new CEO and Board appointmentsMay 12, 2021Management or board changeASX
Adherium Directors' Statement re TakeoverMay 10, 2021Acquisition or disposalASX
Appendix 4C - quarterlyApr 30, 2021Quarterly reportASX
Adherium response to Respiri announcementApr 29, 2021Other filingsASX
Bidder's StatementApr 29, 2021Offer documentASX
Adherium investor presentationMar 17, 2021Other filingsASX
Adherium secures $18m share placement commitmentMar 17, 2021FinancingASX
Adherium agrees rollout to specialist US respiratory centresNov 23, 2020Other filingsASX
Adherium secures $3m funding from ViburnumOct 25, 2020Other filingsASX
CEO update presentation to the EGMJul 23, 2020Other filingsASX
Adherium $5m raise with BioScience Managers Translation FundMay 25, 2020Other filingsASX
Adherium progresses US sales agreement with Monaghan MedicalApr 29, 2020Other filingsASX
Adherium appoints Mike Motion CEO/Director and Anne Bell CFOApr 24, 2020Other filingsASX
Adherium and Planet Innovation partner in tech developmentApr 21, 2020Other filingsASX
Adherium announces collaboration with HGE Health in COPDApr 16, 2020Other filingsASX
Adherium Completes $5.4m Capital RaiseFeb 10, 2020Other filingsASX
Adherium December 2019 Update PresentationDec 18, 2019Other filingsASX
Adherium Non-renounceable Rights Issue Offer DocumentDec 18, 2019FinancingASX
Adherium announces Non-Renounceable IssueDec 10, 2019Other filingsASX
Adherium appoints Peter Stratford CEO and Mike Motion CCONov 21, 2019Other filingsASX
Adherium and Patients Know Best strategic collaborationNov 17, 2019Other filingsASX
Amended - Adherium announces $1.1m notes financingNov 11, 2019Other filingsASX
Response to ASX QueryNov 10, 2019Explanation requestASX
Adherium announces $1.8m secured notes financingAug 21, 2019Other filingsASX
Adherium and Summatix announce strategic initiativeAug 20, 2019Other filingsASX
Adherium Receives further U.S. 510k ClearancesJul 15, 2019Other filingsASX
Employee Share Plan buy-back - Appendix 3CMay 24, 2019Treasury share statusASX
Response to Appendix 4C QueryMay 6, 2019Quarterly reportASX
Adherium Restructures for GrowthDec 12, 2018Other filingsASX
Adherium Investor Conference Call PresentationOct 30, 2018Other filingsASX
Adherium and Vitalus Health Launch Commercial ProgramAug 23, 2018Other filingsASX
Adherium Receives Additional US FDA 510(k) ClearanceJul 26, 2018Other filingsASX
Adherium Program with Connecticut Childrens Medical CenterJul 10, 2018Other filingsASX
Adherium Smartinhaler used in Global Mild-Asthma StudiesMay 21, 2018Other filingsASX
Adherium launches new global brand HailieMay 16, 2018Other filingsASX
Adherium Announces Program with Vitalus HealthMay 1, 2018Other filingsASX
Adherium receives US FDA 510k OTC clearanceMar 27, 2018Other filingsASX
Asthma Adherence Management FindingsMar 7, 2018Other filingsASX
Adherium Highlights Milestones AchievedDec 20, 2017Other filingsASX
Presentation to AGMNov 29, 2017Other filingsASX
Adherium receives US FDA 510k clearanceAug 31, 2017Other filingsASX
Investor Conference Call PresentationAug 28, 2017Other filingsASX
Commitments Test Entity - Fourth Quarter ReportJul 31, 2017Other filingsASX
Adherium Appoints New CEO to Drive Global GrowthJun 8, 2017Management or board changeASX
Appendix 4C - quarterly December 2016Jan 29, 2017Quarterly reportASX
NICE reports on Adherium Smartinhaler for asthma managementJan 11, 2017Other filingsASX
Adherium Smartinhaler dramatically improves outcomesNov 17, 2016Other filingsASX
Appendix 4C - quarterly for period ended 30 Sept 2016Oct 31, 2016Quarterly reportASX
Key Technology Patent Granted in USOct 19, 2016Other filingsASX
Adherium and AstraZeneca Australia Commercial Pilot ProgramAug 16, 2016Other filingsASX
Adherium Executes Placement to Fidelity InternationalJul 19, 2016FinancingASX
Adherium Smartinhaler in AstraZeneca COPD StudyJun 13, 2016Other filingsASX
Clearance to Market in Canada for Flagship ProductsMar 15, 2016Other filingsASX
Appendix 4D and Interim Consolidated Financial ReportFeb 29, 2016Interim reportASX
Adherium Smartinhaler Technology in Multinational StudyFeb 26, 2016Other filingsASX
New Clinical Data Presented at ERS 2015Feb 11, 2016Other filingsASX
Admission to Official ListFeb 10, 2016Other filingsASX